AIM
PRME icon

ARK Investment Management’s Prime Medicine PRME Stock Holding History

ARK Investment Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.7M Buy
6,246,827
+878,301
+16% +$3.34M 0.17% 77
2025
Q4 		$18.6M Sell
5,368,526
-109,325
-2% -$486K 0.12% 90
2025
Q3 		$30.3M Buy
5,477,851
+3,155,182
+136% +$12.8M 0.18% 75
2025
Q2 		$5.74M Sell
2,322,669
-772,503
-25% -$1.19M 0.04% 104
2025
Q1 		$6.16M Sell
3,095,172
-2,055,061
-40% -$5.24M 0.06% 104
2024
Q4 		$15M Sell
5,150,233
-510,486
-9% -$1.79M 0.13% 77
2024
Q3 		$21.9M Sell
5,660,719
-466,054
-8% -$2.16M 0.2% 62
2024
Q2 		$31.5M Buy
6,126,773
+133,419
+2% +$809K 0.28% 54
2024
Q1 		$42M Buy
5,993,354
+2,855,084
+91% +$21.7M 0.29% 51
2023
Q4 		$27.8M Buy
3,138,270
+515,841
+20% +$3.97M 0.16% 68
2023
Q3 		$25M Buy
2,622,429
+173,230
+7% +$2.25M 0.19% 64
2023
Q2 		$35.9M Buy
2,449,199
+526,922
+27% +$7.36M 0.24% 51
2023
Q1 		$23.6M Buy
1,922,277
+282,293
+17% +$4.6M 0.16% 65
2022
Q4 		$30.5M Buy
+1,639,984
New +$29.6M 0.26% 52

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

ARK Investment Management's PRME Position: Q1 2026 in Review

ARK Investment Management increased its Prime Medicine (PRME) stake by 16% in Q1 2026, buying an estimated $3.34M and bringing the position to 6,246,827 shares worth $21.7M. The position accounts for 0.17% of the portfolio, ranked #77.

ARK Investment Management first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $42M in Q1 2024. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • ARK Investment Management held 6,246,827 shares of Prime Medicine worth $21.7M as of Q1 2026.
  • ARK Investment Management bought 878,301 Prime Medicine shares in Q1 2026, an estimated $3.34M.
  • Prime Medicine made up 0.17% of ARK Investment Management's portfolio in Q1 2026, its #77 holding.
  • ARK Investment Management first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • ARK Investment Management's Prime Medicine position peaked at $42M in Q1 2024.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on ARK Investment Management's 13F filing for Q1 2026, filed 12 May 2026.